OTHER FUNCTIONS TAS::75 0849::TAS; THIS MODIFICATION ADDS FUNDING FOR WA'S 2 AND

为药物发现和开发项目的早期阶段提供合成支持。指定用于合成的化合物来源于DCTD的NExT计划和生物评价委员会（BEC）的建议。本合同所涉及的综合工作源于上述项目。在核心化学成分已经确定或未知的情况下，为提高先导化合物的效力和药效学性质而合成类似物也属于合同范围。此外，合同还将用于根据需要检查选定化合物的纯度和特性。所有重新合成的化合物和中间体的纯度和特性将通过最先进的分析化学方法确定。合成的量一般从200毫克到100克不等。在这些合同下，成功的要约人可能需要通过并行合成来合成小型组合库。大多数作业将提供合成路线的大纲，以及从文献中获得的更常见的详细实验程序。在没有可用程序的情况下，或者当已发表的方法在实践中证明不可靠时，可能需要开发合成方法。

Provide synthesis support for the early stages of the drug discovery and development program. The compounds assigned for the synthesis originate from the DCTD�s NExT program and the Biological Evaluation Committee (BEC) recommendations. The synthesis work involved in this contract originates from the above mentioned programs. Synthesis of analogs in order to improve the potencies and pharmacodynamic properties of lead compounds where the core chemistry is either well established or unknown also would fall within the scope of the contract. In addition, the contracts will be utilized to check the purity and identity of selected compounds as needed. The purity and identity of all resynthesized compounds and intermediates will be established by state-of-the-art analytical chemistry methods. The quantities synthesized would generally vary from 200 mg to 100 grams. Under these contracts the successful Offerors may be required to synthesize small combinatorial libraries by parallel synthesis. Outlines of synthetic routes, and more commonly, detailed experimental procedures obtained from the literature, will be available for the majority of the assignments. Development of synthetic methods may be required in those cases where no procedures are available, or when the published methods prove unreliable in practice.